News Release - October 29, 2007

Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients

Source: Gilead Sciences

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.